MRK: Approves KEYTRUDA
European Commission approves KEYTRUDA plus Padcev for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer
MRK - European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer